{"": [134, 1201, 0, 1212, 1530, 0, 30927, 30989, 0], "Introduction": [1531, 3873, 0], "Reformatting and characterization of the MD65 Ab": [3898, 5457, 0], "Pharmacokinetics of MD65 IgG-YTE": [5458, 7932, 0], "Protection against SARS-CoV-2 lethal infection in K18-hACE2 transgenic mice": [7933, 10968, 0], "SARS-CoV-2 viral load in lungs collected from infected K18-hACE2 mice": [10969, 12316, 0], "Lung histopathological evaluation of Ab-treated K18-hACE2 mice": [12317, 14183, 0], "Anti-SARS-CoV-2 seroconversion in Ab-treated animals": [14184, 15969, 0], "Dose-dependent therapeutic efficacy of MD65": [15970, 18695, 0], "Results and discussion": [3874, 18695, 1], "Recombinant proteins expression": [18705, 20893, 0], "ELISA": [20894, 22256, 0], "BLI analysis": [22257, 23626, 0], "Cells": [23627, 24177, 0], "Plaque reduction neutralization test (PRNT)": [24178, 25870, 0], "Animal experiments": [25871, 28261, 0], "Pharmacokinetics": [28262, 28985, 0], "Measurement of viral RNA by qRT-PCR": [28986, 30231, 0], "Lung histology": [30232, 30762, 0], "Reporting summary": [30763, 30899, 0], "Methods": [18696, 30899, 1], "Supplementary information": [30900, 30989, 1]}